Xiayang Qiu and Ming Zhong left Pfizer and founded Regor Therapeutics in 2018, and within months it was touting a diabetes-and-obesity treatment “strikingly similar” to one being developed at Pfizer, according to the U.S. District Court for the District of Connecticut complaint.
Computer forensic analysis confirmed the two had misappropriated confidential information after the company was tipped off by the May 2020 publication of a 2019 Regor patent ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.